Abstract
We conducted a nationwide record-linked study using all English NHS hospital admission data and mortality statistics from 1999 to 2011 to evaluate the risk of concurrent or subsequent bullous pemphigoid (BP) in a cohort of 2,873,720 individuals with malignant cancers, when compared with a reference cohort. We calculated standardised rate ratios (RRs) based on person-years at risk, comparing the observed and expected numbers of BP cases in the cancer cohort with those in the reference cohort. Overall, the cohort of people with a record of a malignant cancer was not found to be at greater risk of concurrent or subsequent BP than the cohort of people without a record of a malignant cancer (RR 0.96, 95 % CI 0.88–1.04), although elevated risks of BP were found in sub-cohorts of people with either kidney cancer, laryngeal cancer or lymphoid leukaemia. We also similarly analysed the risk of concurrent and subsequent malignant cancers in a cohort of people with a principal diagnosis of BP, and again found no increased risk as compared with the reference cohort (RR 1.00, 95 % CI 0.92–1.09).
Similar content being viewed by others
References
Bastuji-Garin S, Joly P, Picard-Dahan C et al (1996) Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol 132(3):272–276
Breslow NE, Day NE (1987) Statistical methods in cancer research, volume II. The design and analysis of cohort studies. International Agency for Research in Cancer, Lyon; IARC Scientific Publication No. 82, pp 103–115
Chorzelski TP, Jablonska S, Maciejowska E et al (1978) Co-existence of malignancies with bullous pemphigoid. Arch Dermatol 114:964
Durdu M, Baba M, Seçkin D (2011) A case of bullous pemphigoid induced by aspirin. J Am Acad Dermatol 65:443–444
Iwashita K, Matsuyama T, Akasaka E et al (2007) The incidence of internal malignancies in autoimmune bullous diseases. Tokai J Exp Clin Med 32:42–47
Jedlickova H, Hlubinka M, Pavlik T et al (2010) Bullous pemphigoid and internal diseases—a case-control study. Eur J Dermatol 20:96–101
Kasperkiewicz M, Zillikens D (2007) The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 33:67–77
Laing VB, Sheretz EF, Flowers FP (1988) Pemphigoid-like bullous eruption related to ibuprofen. J Am Acad Dermatol 19:91–94
Langan SM, Smeeth L, Hubbard R et al (2008) Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ 337:a180
Li L, Chen J, Wang B, Yao Y, Zuo Y (2009) Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 160:1343–1345
Lindelof B, Islam N, Eklund G et al (1990) Pemphigoid and cancer. Arch Dermatol 126:66–69
Lloyd-Lavery A, Chi C, Wojnarowska F, Taghipour K (2013) The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 149:58–62
Mabrouk D, Gürcan HM, Keskin DB, Christen WG, Ahmed AR (2010) Association between cancer and immunosuppressive therapy—analysis of selected studies in pemphigus and pemphigoid. Ann Pharmacother 44:1770–1776
Morioka S, Sakuma M, Ogawa H (1994) The incidence of internal malignancies in autoimmune blistering diseases: pemphigus and bullous pemphigoid in Japan. Dermatology 189(Suppl 1):82–84
Mullins PD, Choudhury SL (1994) Enalapril and bullous eruptions (case report). BMJ 309(6966):1411
Ogawa H, Sakuma M, Morioka S et al (1995) The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 9:136–141
Ramagopalan S, Wotton C, Handel A et al (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 9:1–8
Stone SP, Schroeter AL (1975) Bullous pemphigoid and associated malignant neoplasms. Arch Dermatol 111:991–994
Venning VA, Wojnarowska F (1990) The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol 123:439–445
Vial T, Descotes J (2003) Immunosuppressive drugs and cancer. Toxicology 185:229–240
Acknowledgments
Over many years, the linked data–files were built by Leicester Gill and Matt Davidson, Unit of Health-Care Epidemiology (UHCE), University of Oxford. David Yeates (UHCE) wrote the software package used for the analysis. The Unit of Health-Care Epidemiology is funded by the English National Institute for Health Research to analyse the linked data (Grant reference number RNC/035/002). The views expressed in this paper do not necessarily reflect those of the funding body.
Conflict of interest
The authors state no conflict of interest.
Ethical approval
Ethical approval for analysis of the record linkage study data was obtained from the Central and South Bristol Multi-Centre Research Ethics Committee (04/Q2006/176).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ong, E., Goldacre, R., Hoang, U. et al. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res 306, 75–80 (2014). https://doi.org/10.1007/s00403-013-1399-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-013-1399-5